ERBB2 and neoplasm: Ertumaxomab is a trifunctional bispecific antibody – targeting HER2 on tumor cells and CD3 on T cells – that can redirect T cells, macrophages, dendritic cells, and natural killer cells to the sites of tumor metastases [86,87].